PE20142332A1 - Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas - Google Patents

Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Info

Publication number
PE20142332A1
PE20142332A1 PE2014001174A PE2014001174A PE20142332A1 PE 20142332 A1 PE20142332 A1 PE 20142332A1 PE 2014001174 A PE2014001174 A PE 2014001174A PE 2014001174 A PE2014001174 A PE 2014001174A PE 20142332 A1 PE20142332 A1 PE 20142332A1
Authority
PE
Peru
Prior art keywords
formulation
macromolecle
aggregation
reduce
physiological conditions
Prior art date
Application number
PE2014001174A
Other languages
English (en)
Inventor
Brian Lobo
Sabrina Lo
Aditya Wakankar
Yuchang John Wang
Rita L Wong
Pierre Goldbach
Hanns-Christian Mahler
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170394&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142332(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of PE20142332A1 publication Critical patent/PE20142332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)

Abstract

REFERIDA A UNA MACROMOLECULA, LA CUAL ES UNA PROTEINA, PARTICULARMENTE, UN ANTICUERPO ANTI-CD20, DONDE EL ANTICUERPO COMPRENDE LA SECUENCIA DE AMINOACIDOS SELECCIONADA DEL GRUPO SEC ID NO:1-15. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA PARA ADMINISTRACION SUBCUTANEA QUE COMPRENDE AL ANTICUERPO Y DE 5% A 20% DE POLIVINILPIRROLIDONA (PVP). DICHA FORMULACION ES UTIL PARA REDUCIR LA INFLAMACION EN EL SITIO DURANTE LA ADMINISTRACION SUBCUTANEA DE UNA MACROMOLECULA
PE2014001174A 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas PE20142332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11543908P 2008-11-17 2008-11-17

Publications (1)

Publication Number Publication Date
PE20142332A1 true PE20142332A1 (es) 2015-01-29

Family

ID=42170394

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001039A PE20120204A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
PE2014001174A PE20142332A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001039A PE20120204A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Country Status (18)

Country Link
US (2) US20110300135A1 (es)
EP (1) EP2358394A4 (es)
JP (2) JP2012509270A (es)
KR (2) KR20110097772A (es)
CN (2) CN102281902B (es)
AR (1) AR074196A1 (es)
AU (1) AU2009313756B2 (es)
BR (1) BRPI0916042A2 (es)
CA (1) CA2742990A1 (es)
CL (1) CL2011001131A1 (es)
HK (1) HK1164750A1 (es)
IL (1) IL212532A0 (es)
MX (1) MX2011005056A (es)
PE (2) PE20120204A1 (es)
RU (1) RU2011124527A (es)
TW (1) TW201021831A (es)
WO (1) WO2010057109A1 (es)
ZA (1) ZA201102998B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
DK2946765T3 (en) 2014-05-23 2016-10-31 Ares Trading Sa Liquid pharmaceutical composition
CN106661562A (zh) * 2014-05-27 2017-05-10 中央研究院 得自类杆菌属的岩藻糖苷酶及其用途
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
JP2020503260A (ja) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CN113365609A (zh) 2019-01-31 2021-09-07 伊勒卓菲公司 颗粒形成和形态
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
WO2020264313A1 (en) * 2019-06-28 2020-12-30 Zymo Research Corporation Compositions for the stabilization of cell-free nucleic acids and methods thereof
EP4027978A1 (en) * 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
TW202406571A (zh) 2022-04-13 2024-02-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
ZA200507805B (en) * 2003-04-09 2006-12-27 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
JP2008510466A (ja) * 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR20100044160A (ko) * 2007-06-12 2010-04-29 와이어쓰 엘엘씨 항-ｃｄ20 치료 조성물 및 방법

Also Published As

Publication number Publication date
KR20110097772A (ko) 2011-08-31
WO2010057109A1 (en) 2010-05-20
IL212532A0 (en) 2011-06-30
MX2011005056A (es) 2011-05-31
CN102281902A (zh) 2011-12-14
JP2015157820A (ja) 2015-09-03
US20140308270A1 (en) 2014-10-16
ZA201102998B (en) 2013-06-26
RU2011124527A (ru) 2012-12-27
CA2742990A1 (en) 2010-05-20
KR20140133588A (ko) 2014-11-19
EP2358394A1 (en) 2011-08-24
TW201021831A (en) 2010-06-16
AR074196A1 (es) 2010-12-29
CN102281902B (zh) 2013-11-13
AU2009313756B2 (en) 2015-02-26
AU2009313756A1 (en) 2010-05-20
JP2012509270A (ja) 2012-04-19
HK1164750A1 (en) 2012-09-28
EP2358394A4 (en) 2013-03-06
BRPI0916042A2 (pt) 2015-11-10
CN103705930A (zh) 2014-04-09
US20110300135A1 (en) 2011-12-08
PE20120204A1 (es) 2012-03-03
CL2011001131A1 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
PE20142332A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
MX344727B (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
PE20120169A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
UY35018A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico.
EA201001002A1 (ru) Твердые липидные микрокапсулы, содержащие гормон роста во внутреннем твердом ядре
AR089507A1 (es) VARIANTES DE Fc DE INMUNOGLOBULINAS
MX347504B (es) Formulaciones concentradas de proteina y usos de las mismas.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
EP3889185A3 (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
RU2014102940A (ru) Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
JP2016539921A5 (es)
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов
RU2014102936A (ru) Композиции противораковой вакцины, содержащей пептид wt1, для трансдермального введения
RU2019126232A (ru) Пептиды и способы для лечения диабета
ATE507818T1 (de) Orale verabreichung eines calcitonins
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2014004132A (es) Señuelos humanos notch1.
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease

Legal Events

Date Code Title Description
FD Application declared void or lapsed